Earlier in the week, drug developer Flamel Technologies
Flamel's only sustainable source of revenue is the royalties and manufacturing revenue it gets from GlaxoSmithKline
Wisely, Flamel is trying to cut back on this cash burn to avoid diluted finances in future, but that cutback is not as visible as it could be. The declining dollar bumped up dollar reported expenses 8% last quarter, and it could have a similar effect in the fourth quarter, with the dollar shrinking lower versus the euro.
Flamel is developing six compounds for partners like Wyeth
Even without details on these partnered drugs, investors can look forward to Flamel releasing data from what it says was a successful phase 1 study of its hepatitis C interferon product. If the data does show Flamel's interferon-XL to be comparable or superior to existing interferons, such as Schering-Plough's
Except for the failure of the Coreg CR compliance study, which Flamel had no control over, the past few months have been a mixed bag for Flamel. Coreg CR royalties have continued to be far below previous expectations, but now interferon-XL looks like a viable compound again.
At a market cap barely above $210 million, shares of Flamel aren't trading as if there's confidence in its future. The sooner Flamel can announce the partnered drugs it is working on or the hard data for interferon-XL, the easier it will be to know whether Flamel's pipeline is holding aces or three-seven off suit.
Flamel is an active pick of our Motley Fool Hidden Gems newsletter. Glaxo and Eli Lilly are selections of the Income Investor newsletter. Whether you like your stocks big or small, dividend-laden or having multibagger written all over them, we've got a newsletter for you.